<SEC-DOCUMENT>0001193125-18-132629.txt : 20180426
<SEC-HEADER>0001193125-18-132629.hdr.sgml : 20180426
<ACCEPTANCE-DATETIME>20180426061602
ACCESSION NUMBER:		0001193125-18-132629
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180426
DATE AS OF CHANGE:		20180426
EFFECTIVENESS DATE:		20180426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		18775977

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d550418ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center">Washington,
D.C. 20549 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:15pt; font-family:arial" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;Filed by the registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;Filed by a party other than the registrant</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR BGCOLOR="#d8e7f6" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Check the appropriate box:</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Preliminary Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY&nbsp;(AS PERMITTED BY RULE 14A-6(E)(2))</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Additional Materials</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Soliciting Material Pursuant to Section 240.14a-12</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><FONT COLOR="#0063c3"><B>AMGEN INC. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center"><I>(Name of Registrant as Specified in Its Charter) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center"><I>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR BGCOLOR="#d8e7f6" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Payment of filing fee (check the appropriate box):</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>No fee required.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11</B></P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(1)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Title of each class of securities to which transaction applies:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(2)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Aggregate number of securities to which transaction applies:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">(3)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Per unit price or
other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(4)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Proposed maximum aggregate value of transaction:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(5)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Total fee paid:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Fee paid previously with preliminary materials.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"><B>Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the&nbsp; offsetting fee was paid
previously. Identify the previous filing by registration statement number, or the Form or Schedule&nbsp; and the date of its filing.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(1)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Amount Previously Paid:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(2)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Form, Schedule or Registration Statement No.:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(3)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Filing Party:</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(4)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Date Filed:</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center">[Subsequent to this filing, the following letter was sent by Amgen Inc. to certain
institutional holders of our common </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center">stock. We encourage our stockholders to similarly consider this letter when casting their vote.] </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g550418g60f13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">April &laquo;&nbsp;&nbsp;&nbsp;&nbsp;&raquo;, 2018 </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;SALUTATION&raquo; &laquo;FIRSTNAME&raquo; &laquo;LASTNAME&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;COMPANYNAME&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;ADDRESS&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;ADDRESS2&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;CITY&raquo;, &laquo;STATE&raquo; &laquo;ZIPCODE&raquo; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Dear &laquo;SALUTATION&raquo; &laquo;LASTNAME&raquo;: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Thank you for your investment in Amgen. By now, you should have received the proxy statement for our upcoming 2018 Annual
Meeting of Stockholders to be held on May&nbsp;22, 2018. I would like to ask for your support by voting with the following recommendations of our Board of Directors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#478ef7"><B>FOR each</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#478ef7"><B>Director Nominee</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Item&nbsp;1:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Election of 13 directors to serve on our Board of
Directors for a term of office expiring at the 2019 annual meeting of stockholders.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#478ef7"><B>FOR</B></FONT></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">Item&nbsp;2:</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Advisory vote to approve our executive compensation.</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT COLOR="#478ef7"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Item&nbsp;3:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent
registered public accountants for the fiscal year ending December&nbsp;31, 2018.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT COLOR="#478ef7"><B>AGAINST</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Item&nbsp;4:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Stockholder proposal for an annual report on the extent to which risks related
to public concern over drug pricing strategies are integrated into our executive incentive compensation.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">As you consider your vote, below is a snapshot of our achievements in 2017 and a summary
of our compensation practices and corporate governance developments: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><U>We executed on our business strategy</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">We seek to develop innovative medicines that address important unmet medical needs in the fight against serious illness. Six
therapeutic areas form the core of our business &#150; cardiovascular, oncology/hematology, neuroscience, inflammation, nephrology, and bone health. Our strategy in these therapeutic areas includes a series of integrated activities to strengthen our
long-term competitive position in the industry. These activities include the strategic priorities of discovering and advancing innovative medicines, developing branded biosimilars, expanding our global geographic reach, deploying next-generation
biomanufacturing facilities, improving drug delivery systems, adhering to a disciplined approach to capital allocation while investing for long-term growth, and transforming Amgen for the future. In 2017, we advanced each of these activities as
discussed below and detailed in our 2018 proxy statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We <FONT COLOR="#478ef7"><B>progressed important product candidates in all six of our therapeutic
areas</B></FONT> and delivered on our annual priorities to execute critical product launches and long-term commercial objectives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our deep experience in biologics development and capabilities in biotechnology manufacturing positions us for
success in the emerging biosimilars market and, in 2017, we significantly <FONT COLOR="#478ef7"><B>advanced our biosimilars portfolio</B></FONT>. We currently have two biosimilars approved by the FDA and the EMA (AMJEVITA&#153;/AMGEVITA&#153;
(biosimilar adalimumab (HUMIRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and MVASI&#153; (biosimilar bevacizumab (Avastin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>)), one biosimilar under FDA and EMA regulatory
review (ABP 980 (biosimilar trastuzumab (Herceptin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>)), and two biosimilar candidates in Phase 3 (ABP 710 (biosimilar infliximab
(REMICADE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>)) and ABP 798 (biosimilar rituximab (RITUXAN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>))). </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"> Page
 2
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">April &laquo;&nbsp;&nbsp;&raquo;, 2018 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We <B><FONT COLOR="#478ef7">secured 80 country/product launches</FONT></B> of new medicines in new indications
around the world and our medicines are now available to patients in approximately 100 countries worldwide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We <B><FONT COLOR="#478ef7">invested in next-generation biomanufacturing</FONT></B> that dramatically reduces
the scale and costs of making biologics while maintaining a reliable, high-quality, compliant supply of medicines. In 2017, our new Singapore facility that utilizes next-generation biomanufacturing was approved for certain commercial scale
production by multiple regulatory agencies, including the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA. In early 2018, we announced that we will invest in greater manufacturing capacity to support the volume
growth that we foresee and, as a result, plan to build a new drug substance manufacturing plant using our next-generation biomanufacturing capability in the U.S. which will add highly skilled jobs here in the U.S. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have built leading <B><FONT COLOR="#478ef7">patient- and provider-friendly device capabilities</FONT></B>
to enhance patient experience and to differentiate our products. Notably, in 2017, we launched the Enbrel Mini&#153; single-dose prefilled cartridge with AutoTouch&#153; reusable auto-injector. Meanwhile, the Neulasta<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Onpro<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> kit continued to grow share and by the end of 2017 represented approximately 60% of Neulasta sales in the U.S.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our <B><FONT COLOR="#478ef7">strong cash flows and balance sheet</FONT></B> (along with our successful
execution of our transformation efforts) allowed continued investment for long-term growth through internal research and development (investing $3.6&nbsp;billion in 2017) and external business development transactions, while simultaneously returning
$6.5&nbsp;billion of capital to our stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We continue to improve our business and operating model through significant transformation and process
improvement efforts. Between 2014 and 2017, we have realized <B><FONT COLOR="#478ef7">approximately $1.5</FONT>&nbsp;<FONT COLOR="#478ef7">billion of transformation and process improvement savings</FONT></B> that were reinvested in product launches,
clinical programs and external business development. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><U>Our financial performance was strong and we invested for
long-term growth while returning substantial capital to our stockholders in 2017</U>. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our <FONT STYLE="white-space:nowrap">one-year</FONT> total shareholder return, or TSR, of 22% and our
five-year TSR of 125% outperformed the <FONT STYLE="white-space:nowrap">one-</FONT> and five-year average TSR of our peer group of 10% and 101%, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">As referenced above, we returned $6.5&nbsp;billion of capital to our stockholders in the form of dividends
($3.4 billion) and stock repurchases ($3.1 billion). Further, we increased our quarterly dividend per share 15% over 2016 (to $1.15 per share for 2017). This year, based on our confidence in the long-term outlook for our business, enhanced by the
Tax Cuts and Jobs Act, and consistent with our ongoing objective to return capital to our stockholders, we executed a tender offer for $10&nbsp;billion in shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><U>Our executive compensation is aligned with our business strategy and is performance-based</U>. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We <B><FONT COLOR="#478ef7">pay for performance</FONT></B>, and pay outcomes reflect the achievements of our
Named Executive Officers, or NEOs, against our short- and long-term performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Compensation is performance-based and, as a consequence, <FONT COLOR="#478ef7"><B></B>&#126;<B></B><B>69% of
our other NEOs&#146; 2017 target direct compensation and </B>&#126;<B></B><B>75% of my target direct compensation</B></FONT> was based solely on our Company&#146;s performance (paid in the form of annual cash incentive awards based on our annual
Company performance goals, stock options, and performance units to be paid based on the Company&#146;s performance over a three-year performance period). We use median values as the reference point for each element of compensation at all levels,
including our NEOs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our compensation program is <B><FONT COLOR="#478ef7">directly linked to our performance and
strategy</FONT></B>. Each year, our Compensation and Management Development Committee approves Company performance goals that are designed to focus our staff members on delivering our financial and operational objectives to drive annual performance,
advance strategic priorities, and position us for longer-term success. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"> Page
 3
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">April &laquo;&nbsp;&nbsp;&raquo;, 2018 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><U>We have implemented compensation best practices, including</U>: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">A substantial <B><FONT COLOR="#478ef7">majority of compensation is performance-based</FONT></B>, including 80%
performance-based long-term incentive equity award grants, for our NEOs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">A <B><FONT COLOR="#478ef7">clawback policy</FONT> </B>and our incentive cash compensation plans contain<B> <FONT
 COLOR="#478ef7">recoupment provisions</FONT></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Robust <B><FONT COLOR="#478ef7">stock ownership and retention guidelines</FONT></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><U>We are committed to corporate governance best practices that are informed by extensive stockholder engagement and feedback</U>. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have a highly-engaged, experienced and <B><FONT COLOR="#478ef7">independent Board</FONT></B>; 12 of the 13
director nominees are independent and we are committed to Board refreshment with an average tenure of ~4.8 years for our director nominees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have a <B><FONT COLOR="#478ef7">lead independent director</FONT></B> role with substantial and specific
duties, and the independent directors have elected Robert A. Eckert to serve as the lead independent director for a third term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have a long-standing practice of <B><FONT COLOR="#478ef7">stockholder engagement</FONT></B>, and in
addition to outreach to investors by our executives and our Investors Relations department, we have engaged in governance-focused outreach activities and discussions with stockholders who hold approximately 52% of our outstanding shares since our
2017 annual meeting of stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><U>We recommend a vote AGAINST the stockholder proposal</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">I am also asking for your vote <U>against</U> the stockholder proposal for an annual report on the extent to which risks
related to public concern over drug pricing strategies are integrated into our executive incentive compensation. Our Board opposes this proposal for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We already provide public disclosure regarding the factors that are integrated into our incentive compensation
policies and the risks related to compensation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">The proposal&#146;s underlying subject matter is our drug pricing and capital allocation decisions. Such
decisions are integral to our ordinary course operations and the proposed report would put us at a competitive disadvantage and be unduly burdensome while not providing meaningful additional information to stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We remain focused on delivering breakthrough treatments for unmet medical needs and are committed to working
with the entire healthcare community to ensure continued innovation and enable patient access to needed medicines. We do this by: </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Investing billions of dollars annually in research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;
</P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Pricing our medicines to reflect the value they provide; </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Partnering with payers to share risk and accountability for health outcomes; </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Providing patient support and education programs and helping patients in financial need access our medicines;
and </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Working with policymakers, patients and other stakeholders to establish a sustainable healthcare system with
access to affordable care and in which patients and their healthcare professionals are the primary decision makers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Our Board has a history of responsiveness to stockholder feedback. We have an annually elected board, utilize majority voting
in <FONT STYLE="white-space:nowrap">non-contested</FONT> elections, provide stockholders with the right to act through a special meeting and by written consent, and a proxy access right for stockholders. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"> Page
 4
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">April &laquo;&nbsp;&nbsp;&raquo;, 2018 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">I realize there are many demands on your time and want to thank you for your
attention to these important issues. We would welcome the opportunity to discuss any of the voting matters in our proxy statement with you. Please do not hesitate to contact Arvind Sood, Vice President, Investor Relations, by telephone at (805) <FONT
STYLE="white-space:nowrap">447-1060</FONT> or via email at investor.relations@amgen.com with any questions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:11pt; font-family:Times New Roman">Sincerely,
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:54%; text-indent:-2%">


<IMG SRC="g550418g63w38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:11pt; font-family:Times New Roman">Robert A. Bradway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:11pt; font-family:Times New Roman">Chairman of the Board, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:11pt; font-family:Times New Roman">Chief Executive Officer and President </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&laquo;SECONDNAME&raquo; </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g550418g60f13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g550418g60f13.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ 2 +0 P$1  (1 0,1 ?_$ !T  0 " @,! 0
M           &!P4(! D* @/_Q  T$  !! ,   4$ @$"! <    $  ,%!@$"
M!P@76);7"1(3%!46$2$B"A@D@2,E,5=A<:'_Q  = 0$!  (# 0$!
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M*D2D1O'?)B;8UA>-B'!V-L)R4A'H,Y7Z&M<HT*'"FZ+.4RI3<"'#J,E+.2)
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M /*O W_0I?\ [XIOHM;FSP@" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MC]%CI'2J%QGMGAZUCJSXBJQR#DT#UKF!,['PS5EN5%HU>@O[#3K<,9_ Q=V
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MZSX;N=MWJ_0D5.T+H0#5BI]8)>JS)+<[3)')5OGZZ$5K%21UJ"?;8**-VUF
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M3&<-8VSMG./TMY?YNI3-H @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @*![>W<[ !_7>
M?$Z!3]>"UZ+^R3)FPX9,E5SF#ZE7S"&(TUN0C)F:$V=G@-=VL:1T>TP?NT/+
M#_GR;;O73=IKO2RK].IB[R[M>^VB\NOJ1(KI]ZGY^+*KA),'5IAGDCK(4I3W
MOY2/:OC5O9M;,FX?EK<66J6(^%,?9>8;:AC76V9L4D0G##Y$36]M+]^^UK<]
M0JKHO=I?ZWO?Y:=Y& >U=,(?J(3FD:U,$5JK2)\>="%Q@<[*&PEUTD8'!1FK
M>T3:)>W1E/!B0&7W PP)DELG5XYT;46V37YK]-4U\]%)F71.^W/1=^ZVMM#X
MDNK]:VKI,Y!&Y)TVI/1[7&AE<[GQI?,_5*U4).&I1P\M'03[YDC8B+'&8;!A
M6RG@G-H$0HVQ01TQF63[)O3SU[^ZW?O\@JKW+;?O3OX:^G/4W3TWU<TU<TVU
MWTWUUWTWUSC.NVNV,9UVUSC_ $SKMC.,XSC_ $SC/^5B9GT@" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M+?O^:_33S);SWWNOSTW?1.'\&URQ,@@" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" (#67JLY:([J%*'B)&1Q!;;TC%ABQC"8\
M_1J1Z$*&Q(U0?4T>/M>2/Q.P_2(@\<@B$IQH4O#.:GDYCIC)+6\];<N_^/,Q
M7>GTZKW?5/W>15T).W*;KKD9*](&I<E.<WI+MQE[9,334;"];+MUCWGJ< 3'
MVZHR]>D)0>/E8$B/K,_&2$+%1\21%C,.8#W?JINT[]$1-<NEE_SOU0Q15MO^
M:KQNMT\OX35$+*N5RLK'#M!*U#V)JV:\X%,M(<+:0IJV<]$+J!YS!ALI<;!&
M6,\PLV/=C@IPS=VPN:Z'3FS+DL#@1Z(B9O*^GGKY:?QN[C)57+YVU\M//7^=
M_>8H6RWN?OO+(F4@.BUVN35/G8W=]N8K0[!KA-,B#"K%(E1%N,E=):/D"'0H
M_P"X1QZ->&VDP'B79-_ *R95[UT^FOFGY]XE_P!O=]4UTW[]==VGF6CS%J&A
M0)5G-AF7!;9:+(34P+7>K):97,%7&!*^\["RELG9>7?C3OX<BWZ9#+RP,-8&
MWL?9K]N^8M^5KV2V_C;3R^ADFFNNO&_=\_JIK@?;[MY6TZ0CK%.OF[^'SI$S
M4SF9D\@RR]GBCJHQ3(T\S)>7;!+.NO%#@U^2>+:GM"YK]L(W$?ON)E;5;Z)F
M1%TW(M_RZ>1CO1/_ &JOUT_/J?4G;.DZ'1FK<M-:.EVJ\B]=:;DC\-5.JA>)
MSG5>KI+.F'\:U1CR>/MSD;*Q^L2[)U9D^X;DE$Q;,BTTW^26^>5;_/\ =OW\
M!=?OFWZ?N3ZII>WEJ;1<A/EY&I&/RKY1;+5VZ,%7CC'G22#JA'WRQ!5,K]M[
M9QX\7>!8!TC)-UU]R5BM 9/<HO8O)3V*[^7.R7ZF2;OJMOE?3YEH*%" ( @"
( ( @" (#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g550418g63w38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g550418g63w38.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0B^4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              (P   /     & &< -@ S
M '< ,P X     0                         !              #P
M(P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !B(    !    <    !
M  %0   5    !@8 &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  0 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M?_;BT&,96QM;&AC& !K6B  .&M:/HJ22G__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #8 +@ P     0 X0DE-! 8
M  < "  !  $! /_N  Y!9&]B90!D0     '_VP"$  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,#
M P,# P,! 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# __  !$( ", \ ,!$0 "$0$#$0'_
MW0 $ ![_Q ""   !! (# 0               0<("00* @4& P$!
M             !    8"  ,% P@'!@<      @,$!08' 0@ $0DA,4$2%%%A
M$W&!D:$B8A46\+'!X3(8"M%"4G*2%X*B,R0E)AD1 0
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MX!FY+(>J/> "T=7PC7O2&)."4@9DRN5R7;,W>E(/4C"?A#5]>N<,J2*2!.A
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MECV^'9V?+X<!4-U<]0MC]^X30>H-;2,=>ZP6A<;>Y[TS]GD:-GFBJA84E_,
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M^SQ_MX ],7][Z?W< >G+[?XL\_?^[EP!Z<O[WT^SE_9P!Z<OO^US^7Z^[OX
M].7X^;/RYX!/3%?>^G@%RG+S_B^GWYS^O/ 'IR_?CY_G]GMQP!Z8O[WT_NX
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-[)_^MG_+G]GU\!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
